盐酸美金刚在改善帕金森痴呆患者认知功能和日常生活能力的疗效

Effect of Memantine Hydrochloride on Improving Cognitive Function and Daily Living Ability in Patients with Parkinson's Disease

目的探讨盐酸美金刚在改善帕金森痴呆患者认知功能和日常生活能力的疗效。方法 2016年1月—2017年12月选取帕金森痴呆患者78例,按照随机数字表法,分为对照组(n=39)和观察组(n=39)。两组均采用多巴丝肼片进行基础治疗,对照组在基础治疗上加用盐酸多奈哌齐片进行治疗,观察组在基础治疗上加用盐酸美金刚片进行治疗,比较两组蒙特利尔认知评估量表(MoCA)、简易智能状态量表(MMSE)、日常生活能力量表(ADL)评分和不良反应发生率。结果相较于对照组,观察组治疗4周、8周、16周后的MMSE[(22.71±3.58)分vs(18.39±3.56)分(t=5.344,P<0.05)]、[(23.47±3.22)分vs(19.65±3.14)分(t=5.304,P<0.05)]、[(26.40±4.38)分vs(21.22±4.28)分(t=5.282,P<0.05)],MoCA[(21.51±2.67)分vs(17.87±2.51)分(t=6.203,P<0.05)]、[(23.89±3.89)分vs(19.63±3.41)分(t=5.143,P<0.05)]、[(25.69±4.88)分vs(21.69±4.84)分(t=3.634,P<0.05)],ADL[(61.51±11.28)分vs(55.38±8.69)分,(t=2.688,P<0.05)]、[(64.37±11.68)分vs(57.61±8.93)分,t=2.871,P<0.05]、[(70.36±12.74)分vs(60.36±10.58)分,(t=3.771,P<0.05)]评分均更高,差异有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(χ~2=0.557,P>0.05)。结论盐酸美金刚可改善帕金森痴呆患者认知功能,提高其日常生活能力,同时不会明显增加不良反应的发生,具备较高安全性。

Objective To investigate the efficacy of memantine hydrochloride in improving cognitive function and daily living ability in patients with Parkinson＇s disease. Methods 78 patients with Parkinson＇s dementia from January 2016 to December 2017 were selected and divided into control group （n=39） and observation group （n=39） according to the random number table method. The two groups were treated with Dopas sputum for basic treatment. The control group was treated with donepezil hydrochloride tablets for basic treatment. The observation group was treated with memantine hydrochloride tablets for basic treatment. Table （MoCA）, Simple Intelligence State Scale （MMSE）, Daily Living Ability Scale（ADL） score, and incidence of adverse reactions were compared. Results Compared with the control group, the MMSE [（22.71±3.58）points vs. （18.39±3.56）points （t=5.344, P〈0.05）] and [（23.47±3.22） after 4 weeks, 8 weeks, and 16 weeks of treatment in the observation group. ） vs. （19.65±3.14）points （t=5.304, P〈0.05）], [（26.40±4.38）points vs. （21.22±4.28） points （t=5.282, P〈0.05）], MoCA[（21.51±2.67）points vs. （17.87±2.51）points （t=6.203, P〈0.05）], [（23.89±3.89）points vs. （19.63±3.41） points （t=5.143, P〈0.05）], [（25.69± 4.88）points vs. 21.69±4.84 points （t=3.634, P〈0.05）],ADL[（61.51±11.28） points vs （55.38±8.69）points,（t=2.688, P〈0.05）], [（64.37±11.68）points vs （57.61±8.93） points（t=2.871, P〈0.05）], [（70.36±12.74）points vs （60.36±10.58）points,（t=3.771, P〈0.0）5], the scores were higher, the difference was statistically significant（P〈0.05）; There was no significant difference in the incidence of adverse reactions between the two groups （χ2=0.557,P〉0.05）. Conclusion Memantine hydrochloride can improve the cognitive function of patients with Parkinson＇s dementia and improve their daily living ability, and it will not significantly increase the incidence of adverse reactions, and has higher safety.